Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 4/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL22300929 | 1.00 | KDM4E (0.47) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL15319570 | 0.93 | KDM4E (0.53) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL2552726 | 0.93 | KDM4E (0.53) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL28603990 | 0.86 | KDM4E (0.47) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL25476040 | 0.86 | KDM4E (0.47) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL21471824 | 0.83 | PRKCA (0.45) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL21471879 | 0.83 | PRKCA (0.45) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL8954153 | 0.81 | KDM4E (0.47) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL4805747 | 0.81 | KDM4E (0.53) | KDM4EDUSP3MEN1KMT2ALMNA | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL20524888 | 0.80 | SLC22A6 (0.50) | LMNASLC22A6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10736867-B2 | Glyceryl 3-hydroxybutyrates for traumatic brain injury | NEUROENERGY VENTURES, INC. (US) | 2020-08-11 | — | — | US | claimed |
| US-20180177753-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR MIGRAINE SYMPTOM MANAGEMENT | NEUROENERGY VENTURES, INC. (US) | 2018-06-28 | — | — | US | claimed |
| US-11638702-B2 | Glyceryl 3-hydroxybutyrates for traumatic brain injury | NeuroEnerygy Ventures, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20200297686-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN INJURY | NeuroEnerygy Ventures, Inc. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10736867-B2 | Glyceryl 3-hydroxybutyrates for traumatic brain injury | NEUROENERGY VENTURES, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3568129-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN INJURY | Neuroenergy Ventures, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| WO-2018132189-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN INJURY | NEUROENERGY VENTURES, INC. (US) | 2018-07-19 | — | — | WO | disclosed |
| US-20180193300-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN INJURY | NEUROENERGY VENTURES, INC. (US) | 2018-07-12 | — | — | US | disclosed |
| US-9925164-B1 | Glyceryl 3-hydroxybutyrates for traumatic brain injury | NEUROENERGY VENTURES, INC. (US) | 2018-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297686-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN INJURY | FABP7, B3GAT3, PYGB | KDM4E 3535/4885DUSP3 4584/4885MEN1 3920/4885 |
| US-20180177753-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR MIGRAINE SYMPTOM MANAGEMENT | HTR3B, MGLL, HTR3A | KDM4E 2988/4885DUSP3 3128/4885MEN1 1094/4885 |
| US-10736867-B2 | Glyceryl 3-hydroxybutyrates for traumatic brain injury | FABP7, B3GAT3, PYGB | KDM4E 3535/4885DUSP3 4584/4885MEN1 3920/4885 |
| US-20180193300-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN INJURY | FABP7, B3GAT3, PYGB | KDM4E 3535/4885DUSP3 4584/4885MEN1 3920/4885 |
| US-11638702-B2 | Glyceryl 3-hydroxybutyrates for traumatic brain injury | FABP7, B3GAT3, PYGB | KDM4E 3535/4885DUSP3 4584/4885MEN1 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.